TY - JOUR
T1 - LRRK2 variation and dementia with Lewy bodies
AU - Heckman, Michael G.
AU - Soto-Ortolaza, Alexandra I.
AU - Sanchez Contreras, Monica Y.
AU - Murray, Melissa E.
AU - Pedraza, Otto
AU - Diehl, Nancy N.
AU - Walton, Ronald
AU - Labbé, Catherine
AU - Lorenzo-Betancor, Oswaldo
AU - Uitti, Ryan J.
AU - van Gerpen, Jay
AU - Ertekin-Taner, Nilüfer
AU - Smith, Glenn E.
AU - Kantarci, Kejal
AU - Savica, Rodolfo
AU - Jones, David T.
AU - Graff-Radford, Jonathan
AU - Knopman, David S.
AU - Lowe, Val J.
AU - Jack, Clifford R.
AU - Petersen, Ronald C.
AU - Parisi, Joseph E.
AU - Rademakers, Rosa
AU - Wszolek, Zbigniew K.
AU - Graff-Radford, Neill R.
AU - Ferman, Tanis J.
AU - Dickson, Dennis W.
AU - Boeve, Bradley F.
AU - Ross, Owen A.
N1 - Funding Information:
CL is the recipient of a FRSQ postdoctoral fellowship and is a current Younkin Fellow (2015). The Mayo Clinic is a Morris K. Udall Parkinson's Disease Research Center of Excellence (NINDS P50 #NS072187), an Alzheimer's Disease Research Center (NIA P50 AG016574) and is supported by the Mayo Clinic Study of Aging (NIA U01 AG006786), NINDS R01 NS078086, NIH R01NS076471, NIH R01 AG015866, Michael J. Fox Foundation, Mayo Clinic AD and related dementias genetics program, The Little Family Foundation and the Mangurian Foundation for Lewy body research. ZKW is funded by the Mayo Clinic Center for Regenerative Medicine, Mayo Clinic Center for Individualized Medicine, Mayo Clinic Neuroscience Focused Research Team, and the gift from Carl Edward Bolch, Jr. and Susan Bass Bolch. The funding sources for this study had no role in the study design, in the collection, analysis, and interpretation of data, in the writing of the manuscript, or in the decision to submit the article for publication.
Publisher Copyright:
© 2016 Elsevier Ltd
PY - 2016/10/1
Y1 - 2016/10/1
N2 - Introduction The leucine-rich repeat kinase 2 (LRRK2) gene contains several variants that cause Parkinson's disease (PD) and others that modify PD risk. However, little is known about the role of LRRK2 in dementia with Lewy bodies (DLB). Aims of this study were to screen DLB patients for pathogenic LRRK2 variants and to evaluate associations between common LRRK2 variants and risk of DLB. Methods 417 clinical DLB patients and 1790 controls were included in the primary analysis. Additionally, 355 Lewy body disease patients assessed as having a high likelihood of clinical DLB based on neuropathological findings were included in secondary analysis. Seven pathogenic LRRK2 variants were assessed in patients, while 17 common LRRK2 exonic variants and 1 GWAS-nominated common LRRK2 PD-risk variant were evaluated for association with DLB. Results We identified carriers of 2 different pathogenic LRRK2 variants. One clinical DLB patient was a p.G2019S carrier, while in the pathological high likelihood DLB series there was one carrier of the p.R1441C mutation. However, examination of clinical records revealed the p.R1441C carrier to have PD with dementia. Evaluation of common variants did not reveal any associations with DLB risk after multiple testing adjustment. However, a non-significant trend similar to that previously reported for PD was observed for the protective p.N551K-R1398H-K1423K haplotype in the clinical DLB series (OR: 0.76, P = 0.061). Conclusion LRRK2 does not appear to play a major role in DLB, however further study of p.G2019S and the p.N551K-R1398H-K1423K haplotype is warranted to better understand their involvement in determining DLB risk.
AB - Introduction The leucine-rich repeat kinase 2 (LRRK2) gene contains several variants that cause Parkinson's disease (PD) and others that modify PD risk. However, little is known about the role of LRRK2 in dementia with Lewy bodies (DLB). Aims of this study were to screen DLB patients for pathogenic LRRK2 variants and to evaluate associations between common LRRK2 variants and risk of DLB. Methods 417 clinical DLB patients and 1790 controls were included in the primary analysis. Additionally, 355 Lewy body disease patients assessed as having a high likelihood of clinical DLB based on neuropathological findings were included in secondary analysis. Seven pathogenic LRRK2 variants were assessed in patients, while 17 common LRRK2 exonic variants and 1 GWAS-nominated common LRRK2 PD-risk variant were evaluated for association with DLB. Results We identified carriers of 2 different pathogenic LRRK2 variants. One clinical DLB patient was a p.G2019S carrier, while in the pathological high likelihood DLB series there was one carrier of the p.R1441C mutation. However, examination of clinical records revealed the p.R1441C carrier to have PD with dementia. Evaluation of common variants did not reveal any associations with DLB risk after multiple testing adjustment. However, a non-significant trend similar to that previously reported for PD was observed for the protective p.N551K-R1398H-K1423K haplotype in the clinical DLB series (OR: 0.76, P = 0.061). Conclusion LRRK2 does not appear to play a major role in DLB, however further study of p.G2019S and the p.N551K-R1398H-K1423K haplotype is warranted to better understand their involvement in determining DLB risk.
KW - Dementia with Lewy bodies
KW - Genetics
KW - LRRK2
KW - Parkinson's disease
UR - http://www.scopus.com/inward/record.url?scp=84994316356&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84994316356&partnerID=8YFLogxK
U2 - 10.1016/j.parkreldis.2016.07.015
DO - 10.1016/j.parkreldis.2016.07.015
M3 - Article
C2 - 27521182
AN - SCOPUS:84994316356
SN - 1353-8020
VL - 31
SP - 98
EP - 103
JO - Parkinsonism and Related Disorders
JF - Parkinsonism and Related Disorders
ER -